Under the terms of the agreement, PSC will offer a complete solution of Geospiza software and PSC services to reduce operational costs and regulatory risks for organizations that need to integrate genetic analyses into their manufacturing process.
“Manual genetic analysis continues to be a major bottleneck for companies trying to bring new and innovative genetic tests and personalized treatments to market,” said Rob Arnold, president of Geospiza.
“Geospiza and PSC are committed to helping our clients manage the regulatory requirements of genetic analysis automation in a full-scale commercial environment,” Arnold added.
“We are approaching this market together because the biotech, pharmaceutical and diagnostic industries are at a true inflection point,” said Patricia Rossman, Vice President of Pharmaceutical Services Corporation. “PSC and Geospiza share a common vision for delivery excellence.”
PSC will target the combined offering to manufacturers of vaccines, novel bio-therapeutics and gene therapies which are regulated by U.S. Food and Drug Administration (FDA) requirements for aseptic processing for the manufacture of sterile drug and biological products under current Good Manufacturing Practice (cGMP) regulations (21 CFR parts 210 and 211).
Facilities and agencies involved in environmental monitoring, food safety testing, molecular diagnostic testing and clinical trial efforts expected to benefit as well.